-
2 weeks ago | 
uspharmacist.com | Robert Davidson
US Pharm. 2025;50(6)1. On May 12, 2025, President Donald Trump issued an Executive Order that is aimed to reduce the prices that Americans pay for their medications. The order proposed a system wherein the prices of certain drugs in the United States would be tied to the prices paid in other countries, especially those with similar economic conditions.
-
2 months ago | 
uspharmacist.com | Robert Davidson
US Pharm. 2025;50(4):1. On a recent warm afternoon, my wife and I were turned away from a favorite reservoir and trail system in northwest New Jersey due to the detection of avian flu in dead or sick birds in the area. The site, the notice read, would be closed until further notice.
-
Mar 14, 2025 | 
uspharmacist.com | Robert Davidson
US Pharm. 2025;50(3):4. Vertex Pharmaceuticals, Inc., recently announced that the FDA approved suzetrigine (Journavx), an oral, nonopioid, highly selective pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. In clinical trials, suzetrigine was shown to be an effective, well-tolerated medication without evidence of addictive potential, the manufacturer said.
-
Jan 15, 2025 | 
uspharmacist.com | Robert Davidson
US Pharm. 2025;50(1):1. Cleveland Clinic Genome Center researchers unraveled how microglia, specialized immune cells that respond to threats such as bacteria and viruses, also drive neuroinflammation in Alzheimer’s disease (AD). Published in Alzheimer’s & Dementia, the study integrated drug databases with real-world patient data to repurpose FDA-approved drugs to target disease-associated microglia in AD without affecting healthy microglia cells.
-
Dec 11, 2024 | 
uspharmacist.com | Robert Davidson
Research from the University of California, Irvine, demonstrates how disruption of the circadian clock, the body’s internal, 24-hour biological pacemaker, may accelerate the progression of colorectal cancer by affecting the gut microbiome and intestinal barrier function. This discovery may offer insights into prevention and treatment strategies.
-
Nov 15, 2024 | 
uspharmacist.com | Robert Davidson
US Pharm. 2024;49(11):3. Two recently reported clinical studies add to the overall store of knowledge of diabetes on a molecular level, portending possible prevention and treatment advances against the ubiquitous endocrine disease. Researchers at the Jackson Laboratory (JAX) in Bar Harbor, Maine, discovered that DNA sequence changes that are known to increase a person’s risk for diabetes are linked to how well pancreatic cells handle molecular stress.
-
Oct 17, 2024 | 
uspharmacist.com | Robert Davidson
US Pharm. 2024;49(10):3. Artificial intelligence (AI) has the potential to accelerate the process of identifying new molecules for mental health disorders drug development, according to a recent study by scientists from Uppsala University in Sweden. By predicting the three-dimensional structures of key receptors, the authors of the research in Science Advances contend, AI could speed up the drug-development process.
-
Sep 18, 2024 | 
uspharmacist.com | Robert Davidson
US Pharm. 2024;49(9):3. Endometriosis is a common, burdensome, chronic disease that affects more than 11% of women of reproductive age in the United States and 190 million women worldwide. Early diagnosis remains a major clinical and public health challenge: The average time to diagnose endometriosis is 7 years after the onset of symptoms, which include abdominal pain and cramping before, during, and after menstruation, among others.
-
Aug 16, 2024 | 
uspharmacist.com | Robert Davidson
US Pharm. 2024;49(8):4. For many parents, cutting into their children’s screen use is a losing battle. Recent research from the University of California, San Francisco (UCSF), however, has found that restricting screens in bedrooms and at mealtimes and modeling healthy practices at home are effective measures.
-
Jul 18, 2024 | 
uspharmacist.com | Robert Davidson
U.S. Pharm. 2024;49:1. Chronic obstructive pulmonary disease (COPD) is a significant global health burden. Characterized by significant airflow decrease in the lungs, it results in cough and dyspnea. This November 11 and 12, the world’s largest educational symposium on COPD, organized by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), is taking place in Philadelphia and online.
